.jpg)
PROTEASOME INHIBITOR
Patent number:
EP24382811
No items found.
Researchers at the Universitat Jaume I and the Max Planck Institute have developed new proteasome inhibitors with pharmacological properties different from those developed until now.
Countries:
Spain
Regions:
Valencian Community
Centers:
UNIVERSITAT JAUME I
Other entities:
Max Planck Institute
Sectors:
Health
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
SDG03: Good health and well-being
Applications
- Compounds with higher affinity and more specific. - Improved properties with respect to commercial drugs (higher target selectivity and increased affinity).
Comments
The technology is the subject of a project to valorize research results.